Details for New Drug Application (NDA): 206165
✉ Email this page to a colleague
NDA 206165 describes NAFTIFINE HYDROCHLORIDE, which is a drug marketed by Amneal, Taro, and Xiromed, and is included in six NDAs. It is available from two suppliers. Additional details are available on the NAFTIFINE HYDROCHLORIDE profile page.
The generic ingredient in NAFTIFINE HYDROCHLORIDE is naftifine hydrochloride. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naftifine hydrochloride profile page.
The generic ingredient in NAFTIFINE HYDROCHLORIDE is naftifine hydrochloride. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naftifine hydrochloride profile page.
Summary for 206165
| Tradename: | NAFTIFINE HYDROCHLORIDE |
| Applicant: | Amneal |
| Ingredient: | naftifine hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | GEL;TOPICAL | Strength | 1% | ||||
| Approval Date: | Mar 20, 2019 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
